Combination Etoposide-Prednisolone-Vincristine-Cyclophosphamide Regimens: A Retrospective Toxicity Profile Analysis

Authors

  • Stavrou I Department of Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki, Greece Author
  • Krumins I Department of Haematology, University of Latvia, Riga, Latvia Author
  • Oja T Department of Clinical Pharmacology, Tallinn University of Technology, Tallinn, Estonia Author

DOI:

https://doi.org/10.5281/zenodo.22643971

Keywords:

EPOCH chemotherapy toxicity, CHOP regimen adverse effects, vincristine-induced peripheral neuropathy, anthracycline cardiotoxicity, chemotherapy-induced myelosuppression

Abstract

Background: Etoposide, prednisolone (or prednisone), vincristine, and cyclophosphamide form the shared pharmacological
backbone of EPOCH, CHOP, CVP, and hyper-CVAD, chemotherapy regimens administered, often sequentially, to overlapping
populations of patients with aggressive lymphoma, follicular lymphoma, and acute lymphoblastic leukemia. Objective: This
retrospective case-study analysis synthesizes the published toxicity literature on this regimen family to characterize the pattern,
severity, and overlap of treatment-related morbidity encountered in clinical practice. Methods: Peer-reviewed retrospective cohort
studies, prospective trial toxicity reports, pharmacovigilance analyses, and mechanistic reviews describing hematologic,
neurologic, cardiac, infectious, and genitourinary or metabolic toxicity of this regimen family were identified through structured
literature searches, individually verified against their publisher or indexing records, and narratively synthesized by toxicity domain
rather than pooled statistically. Findings: Myelosuppression is the dominant acute toxicity across all regimens, with severity and
duration scaling from anthracycline-free CVP through CHOP and dose-adjusted EPOCH-R to dose-intensive hyper-CVAD, the latter
producing cytopenias persisting in the majority of patients three months after treatment and a measurable cumulative incidence
of secondary hematologic malignancy at four years. Vincristine-induced peripheral neuropathy is cumulative and genetically
modulated across every regimen; anthracycline-mediated cardiotoxicity accumulates with lifetime anthracycline exposure and is
detectable by echocardiography even with liposomal doxorubicin substitution; febrile neutropenia risk is amplified by advanced
age and, in infusional EPOCH-based regimens, is compounded by catheter-associated infection; and cyclophosphamide-related
hemorrhagic cystitis together with corticosteroid-related metabolic and infectious effects scale with per-cycle dose. Conclusions:
Etoposide-prednisolone-vincristine-cyclophosphamide-containing regimens share a mechanistically coherent, overlapping toxicity
architecture whose cumulative components, chiefly anthracycline cardiotoxicity and vincristine neuropathy, warrant explicit
consideration whenever more than one regimen from this family is used across a patient's treatment course.
Keywords: EPOCH chemotherapy toxicity; CHOP regimen adverse effects; vincristine-induced peripheral neuropathy; anthracycline
cardiotoxicity; chemotherapy-induced myelosuppression

References

Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 11(8):1573-1582, DOI:10.1200/JCO.1993.11.8.1573.

Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. Journal of Clinical Oncology, 18(21):3633-3642, DOI:10.1200/JCO.2000.18.21.3633.

Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. New England Journal of Medicine, 368(15):1408-1416, DOI:10.1056/NEJMoa1214561.

Tsukamoto Y, Kiyasu J, Choi I, Kozuru M, Uike N, Utsunomiya H, et al. (2020) Efficacy and safety of the modified EPOCH regimen (etoposide, vincristine, doxorubicin, carboplatin, and prednisolone) for adult T-cell leukemia/lymphoma: a multicenter retrospective study. Clinical Lymphoma, Myeloma and Leukemia, 20(7):e445-e453, DOI:10.1016/j.clml.2020.03.008.

Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W (2006) Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas. Cancer, 107(5):1014-1022, DOI:10.1002/cncr.22093.

Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Journal of Clinical Oncology, 18(3):547, DOI:10.1200/JCO.2000.18.3.547.

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105(4):1417-1423, DOI:10.1182/blood-2004-08-3175.

Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K (2016) Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) with or without rituximab as first-line therapy for aggressive non-Hodgkin lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 16(2):76-81, DOI:10.1016/j.clml.2015.11.012.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM (2018) Complications associated with dose-adjusted EPOCH-rituximab therapy for non-Hodgkin lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 18(12):781-787, DOI:10.1016/j.clml.2018.08.014.

Gill S, Lane SW, Crawford J, Cull G, Joske D, Marlton P, Mollee PN, Prince HM, Seymour JF (2008) Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology, 87(9):727-734, DOI:10.1007/s00277-008-0488-6.

Triarico S, Romano A, Attina G, Capozza MA, Maurizi P, Mastrangelo S, Ruggiero A (2021) Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment. International Journal of Molecular Sciences, 22(8):4112, DOI:10.3390/ijms22084112.

Li L, Sajdyk T, Smith EML, Chang CW, Li C, Ho RH, Hutchinson R, Wells E, Skiles JL, Winick N, Martin PL, Renbarger JL (2019) Genetic variants associated with vincristine-induced peripheral neuropathy in two populations of children with acute lymphoblastic leukemia. Clinical Pharmacology & Therapeutics, 105(6):1421-1428, DOI:10.1002/cpt.1324.

Yang QY, Hu YH, Guo HL, Xia Y, Zhang Y, Fang WR, Li YM, Xu J, Chen F, Wang YR, Wang TF (2021) Vincristine-induced peripheral neuropathy in childhood acute lymphoblastic leukemia: genetic variation as a potential risk factor. Frontiers in Pharmacology, 12:771487, DOI:10.3389/fphar.2021.771487.

Mufti K, Cordova M, Scott EN, Trueman JN, Lovnicki JM, Loucks CM, Rassekh SR, Ross CJD, Carleton BC (2024) Genomic variations associated with risk and protection against vincristine-induced peripheral neuropathy in pediatric cancer patients. npj Genomic Medicine, 9:56, DOI:10.1038/s41525-024-00443-7.

Watson C, Gadikota H, Barlev A, Beckerman R (2022) A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen. Journal of Drug Assessment, 11(1):1-11, DOI:10.1080/21556660.2022.2073101.

Rihackova E, Rihacek M, Vyskocilova M, Valik D, Elbl L (2023) Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future. Frontiers in Cardiovascular Medicine, 10:1243531, DOI:10.3389/fcvm.2023.1243531.

Septianda I, Alsagaff MY, Pikir BS, Ashariati A, Fuadi MR, Zahra F (2025) Effect of cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone (CHOP) chemotherapy regimens on left ventricular systolic function and cardiac structural abnormalities in non-Hodgkin lymphoma patients. Journal of the Egyptian National Cancer Institute, 37(1):29, DOI:10.1186/s43046-025-00288-w.

Lu B, Shen L, Ma Y, Qi J, Li Y, Wang Z, Han L, Zhong M (2022) Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: a systematic review and meta-analysis. Frontiers in Pharmacology, 13:1060668, DOI:10.3389/fphar.2022.1060668.

Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS (2014) Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Journal of Korean Medical Science, 29(11):1493-1500, DOI:10.3346/jkms.2014.29.11.1493.

Matsuda K, Jo T, Shimura A, Honda A, Taoka K, Masamoto Y, Matsui H, Fushimi K, Yasunaga H, Kurokawa M (2022) Risk of febrile neutropenia in very elderly patients aged >=80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan. British Journal of Haematology, 197(3):301-309, DOI:10.1111/bjh.18028.

Almalag HM, Alasmari SS, Alrayes MH, Binhameed MA, Alsudairi RA, Alosaimi MM, Alnasser GA, Abuzaid RA, Khalil N, Abouzaid HH, Alarfaj AS (2020) Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: a cohort study and comprehensive literature review. Journal of Oncology Pharmacy Practice, 27(2):340-349, DOI:10.1177/1078155220920690.

Wakasugi Y, Noda S, Ikuno Y, Horie M, Kito K, Minamiguchi H, Terada T (2019) Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study. Journal of Pharmaceutical Health Care and Sciences, 5:24, DOI:10.1186/s40780-019-0153-3.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schoder H, Zelenetz AD, Leonard JP (2019) Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303. Journal of Clinical Oncology, 37(21):1790-1799, DOI:10.1200/JCO.18.01994.

Downloads

Published

2026-06-29